Orexigen Therapeutics Культура компании

Mr. Thomas P. Lynch has been an Executive Vice President, General Counsel and Secretary of Orexigen Therapeutics, Inc. since December 1, 2015. Mr. Lynch is responsible for global legal affairs and compliance operations. Mr. Lynch joined Orexigen Therapeutics, Inc. from Novartis where, since 2012, he served as senior legal counsel in two divisions, including leading global legal and compliance support for Novartis Pharmaceuticals' neuroscience franchise and advising on business development and alliance management with partners in Europe and the U.S. Earlier, Mr. Lynch spent almost ten years with Boston Scientific Corporation in a variety of legal roles and nearly six years practicing corporate law for Dorsey & Whitney LLP. He holds a juris doctorate degree from Boston College Law School, a master's degree in teaching from the University of St. Thomas and a bachelor's degree in history from Stanford University.

Stephen A. Moglia has been the Chief Accounting Officer at Orexigen Therapeutics, Inc. since December 11, 2015 and serves as its Controller and Vice President.

Mr. Jason Keyes has been the Chief Financial Officer and Senior Vice President of Orexigen Therapeutics, Inc. since June 8, 2016. Mr. Keyes joined Orexigen in 2013 and most recently served as Vice President of Finance and served as a key financial advisor to executive management setting corporate business and financial strategy. Prior to joining Orexigen, Mr. Keyes served as Senior Director of Finance at Amylin Pharmaceuticals, Inc., which was acquired by Bristol Myers Squibb in 2012. Previously, he worked in finance and corporate strategy at Amgen, Inc. and at Baxter Healthcare Corporation. He is also a licensed professional engineer and has six years of experience in the environmental engineering industry. He holds Bachelor of Science and Master of Science degrees in Civil Engineering from Stanford University and a Master of Business Administration degree from the Anderson School at the University of California, Los Angeles.

Dr. Thomas R. Cannell, DVM, has been Chief Operating Officer of Orexigen Therapeutics, Inc. since June 8, 2016 and Executive Vice President since July 2015. Dr. Cannell has been President of Global Commercial Products at Orexigen Therapeutics, Inc. since June 8, 2016. He served as the Chief Commercial Officer of Orexigen Therapeutics, Inc. from March 2015 to June 8, 2016. Dr. Cannell served as the President and Managing Director at Merck Canada Inc. (formerly, Merck Frosst Canada Ltd.) since January 1, 2013. He joined to Merck Europe/Canada region from Japan, where in 2010 he joined the Japanese organization as Vice President and Executive Officer, Head of Marketing and Chief Strategy Officer. In this position, he played an instrumental role in the development of the Japanese 10-Year Strategic Plan, while leading business innovation and other key strategic initiatives. While in Japan, he oversaw the product launches of Gardasil ?? , Cubicin ?? , Cancidas ?? and Rotateq ??. He served as the Head of Marketing and Strategy for MSD Japan. He began his career with Merck Frosst Canada in 1987 as a Sales Representative and over the course of his career has held positions of increasing responsibility in strategic planning, marketing and sales. Dr. Cannell has demonstrated leadership in developing and implementing business plans designed to support Merck's strategic growth initiatives in the United States and abroad. In 2007, as the General Manager for the New Commercial Model, he led the team responsible for designing and testing the business model. He is a Member of Canada's Research-Based Pharmaceutical Companies (Rx&D) Board of Directors. He has also served in the U.S. Army Reserves (currently inactive) since 1987. Dr. Cannell received his BS and Doctor of Veterinary Medicine (DVM) from Washington State University and practiced as a Small Animal Veterinarian in Washington State.

Mr. Brian Longstreet has been Senior Vice President of Global Market Access and Development at Orexigen Therapeutics, Inc. since May 3, 2016. Mr. Longstreet is responsible for leading Orexigen's market access and development strategy, relationships and execution. He served as a Managing Director of Global Health Investment Fund I, LLC at Lion's Head Global Partners, Investment Arm. Mr. Longstreet served as Vice President of West Commercial Operations Group at Merck Sharp & Dohme Corp. He has over 25 years of diverse leadership experience to Orexigen including roles in Global General Management, Marketing, Sales, Finance, and Market Access. He joined Orexigen from Merck & Co., where he held various management positions including Vice President of U.S. Managed Markets and Policy. He served as Managing Director of Global Health Investment Fund, Merck's venture capitalinvestment fund focused on healthcare technologies and adjacencies to the core pharmaceutical business. He also served as Managing Director for the Human Health business of MSD Ireland, Merck's Irish subsidiary. He is a well-rounded background and understanding of building, producing, and sustaining success with specialty and primary care pharmaceutical products.

Dr. Peter Flynn, also known as Pete, Ph.D. served as Senior Vice President of Early Program Development at Fate Therapeutics, Inc. since February 2013. Mr. Flynn joined Orexigen in 2014, has more than 15 years of experience in biopharmaceutical research and development. he served as Vice President of Biologic Therapeutics at Fate Therapeutics, Inc. from May 2011 to February 2013. He served as Senior Director of Protein Discovery & iPSC Technology at Fate Therapeutics, Inc. He has been involved in biotechnology start-ups with a focus on biologic therapeutics for more than 10 years. Prior to joining Fate Therapeutics, he served as Vice President of Research at REN Pharmaceuticals, Inc. Prior to joining Ren Pharmaceuticals, Mr. Flynn served as a Director of Biochemistry Research at KaloBios Pharmaceuticals. He was a member of the original KaloBios team and was integral in the development of the platform antibody HumaneeringTM technology. He played a major role in the identification and preclinical development of KaloBios' three initial therapeutic antibodies for the treatment of infectious disease, inflammation and cancer. He was also project manager for KaloBios's service business, completed many projects for both large pharma and small biotech clients. Prior to the formation of KaloBios, he was a researcher at UCSF Comprehensive Cancer Center. He is the author of many publications and patents in the areas of cellular signal transduction and antibody engineering. Mr. Flynn gained a PhD from the ICRF London (Cancer Research UK) and a first class BSc in molecular biology from University College London.

Ms. Toni D. Foster MA, R.A.C. serves as Senior Vice President of Project Management Office & Clinical Operations at Orexigen Therapeutics, Inc. Ms. Foster joined Orexigen in 2012 and previously managed the enrollment and overall conduct of the Light Study cardiovascular outcomes trial. She served as the Senior Director of Clinical Operations at BioVascular, Inc. She has over fifteen years of clinical development industry experience in over 35 clinical trials from Phase I to IV. She has supervised and managed international teams of 250+ personnel, inclusive of investigators, CRO personnel, and the departmental team. She has implemented clinical research protocols, developed and managed all logistics for global trials, established quality methods, and provided project management at all stages of product development. Ms. Foster has experience in preparing regulatory submissions to the FDA and other Regulatory Agencies, inclusive of INDs/CTAs and NDAs. Therapeutic areas of experience have included anti-infective, lupus nephritis, antiphospholipid syndrome (thrombosis), various CNS disorders, psoriasis, Alzheimer's disease, and male erectile dysfunction. Ms. Foster was previously employed at La Jolla Pharmaceutical Company (Sr. Director, Clinical Operations) from 2000 to 2005. She held positions of increasing responsibility at two of the largest international CROs, Quintiles, Inc. and PAREXEL International. Ms. Foster holds her B.S. degree from Michigan State University, her M.A. in Organizational Management from University of Phoenix, and has U.S. Regulatory Affairs Certification designation.